Claimed effect · Thymalin

Does Thymalin help with mortality in the elderly?

C
Grade C — weak human evidence1 long-term series (n=266, 6–8 yr) · effect size: moderate
Short answerWeak human evidence. 1 long-term series (n=266, 6–8 yr): enough to be interesting, not enough to count on. Where an effect is seen it is a moderate effect. Khavinson and Morozov report 2.0–2.1-fold lower mortality in thymalin-treated participants against a control group, and 4.1-fold with annual thymalin plus epithalamin. The abstract does not describe how participants were allocated or whether anyone was blinded; the same authors developed the products.

What the studies show

Khavinson and Morozov report 2.0–2.1-fold lower mortality in thymalin-treated participants against a control group, and 4.1-fold with annual thymalin plus epithalamin. The abstract does not describe how participants were allocated or whether anyone was blinded; the same authors developed the products.

“Such a significant improvement in the health state of the peptide-treated patients correlated with decreased mortality rate during observation: 2.0-2.1-fold in the Thymalin-treated group; 1.6-1.8-fold in the Epithalamin-treated group; 2.5-fold in the patients treated with Thymalin plus Epithalamin as compared to the control.”

Verbatim, from the abstractKhavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett, 2003;24:233–240

A few small or poorly-controlled human studies. Enough to be interesting; not enough to count on. Most of what gets called “clinically proven” online lives here.

  1. 1
    Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life.Neuro Endocrinol Lett, 2003;24:233–240266 elderly participants, 6–8 years. No randomisation or blinding described.

In context

Thymalin is a mixture of short peptides extracted from calf thymus, developed in Soviet-era St Petersburg and sold as an immune 'bioregulator'. The evidence behind its anti-ageing reputation is a 2003 report of 266 elderly people followed for six to eight years, which claims halved mortality but describes neither randomisation nor blinding. No trial outside that group's institute exists in the indexed literature. It is not approved in any region this site covers.

Thymalin is not approved (russia only). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Thymalin proven to help with mortality in the elderly?
No. The human evidence is weak (1 long-term series (n=266, 6–8 yr)); LYO grades it C.
What studies are behind the grade?
Khavinson and Morozov report 2.0–2.1-fold lower mortality in thymalin-treated participants against a control group, and 4.1-fold with annual thymalin plus epithalamin. The abstract does not describe how participants were allocated or whether anyone was blinded; the same authors developed the products.
Is Thymalin approved for this?
No. Thymalin is not approved (Russia only); it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for Thymalin

Written and maintained by LYO Research — how pages are written and checked. Reviewed 23 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →